Health & Fitness 
Health and Fitness
Health and Fitness 
Tue, February 10, 2009
Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.
PORTLAND, Ore.--([ BUSINESS WIRE ])--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, today announced that it has extended its supply agreement with Ferring Pharmaceuticals, Inc. for the sale of its needle-free drug vial adapters. The new agreement extends the most recent agreement for an additional three years with two consecutive one year renewal options.
The Bioject drug vial adapter is a unique needle-free FDA 510(k)-released product. This vial adapter allows withdrawal of medication, withdrawal and transfer of diluents and reconstitution without the use of a needle. The non-sharps plastic device is used with Ferring's proprietary drug.
"We look forward to continuing our positive relationship with Ferring Pharmaceuticals and are pleased that they have decided to extend utilization of our unique needle-free vial adapter technology for another three to five years,' said Ralph Makar, Bioject's President and CEO. "The vial adapter offers many improvements and advantages to accessing medication and reconstitution of medication without the use of a needle and we have shown this to be very successful in other applications. The removal of needles from any market is an advantage for everyone," said Makar.
Bioject Medical Technologies Inc.,based in Portland, Oregon, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS provide an empowering technology and works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information about Bioject, visit [ www.bioject.com ].